|Articles|June 20, 2019
IDDI & Roche Identify DFS As Way Forward In Early Breast Cancer
Advertisement
Commissioned by Roche Germany, IDDI has found data that suggests that it is appropriate to use disease-free survival as a surrogate for overall survival in trials in HER-2-positive breast cancer.
To learn more about their findings, click
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Clinical Trials in 2026: Platformization, AI Fluency, and the Redrawing of the Value Chain
2
Breaking Out of AI Pilot Mode in Clinical Development
3
ACT Brief: Community Sites Compete on Readiness, COA Licensing Bottlenecks Slow Start-Up, and AI’s Foundations in Pharmacovigilance
4
ACT Brief: Community Sites Prove Readiness, Platformization Reshapes Clinical Ops, and AI Targets Precision Care at JPM
5